retatrutide ema approval status 2025 FDA Timeline 2026-2028: Filing & Retatrutide Phase 3: TRIUMPH Program

While the study showed that GLP-1 agonists are associated with decreased risks of certain severe health outcomes like pneumonia, suicidal ideation, and alcohol use disorder, they may increase the risk of other outcomes, including gastroesophageal reflux disease, nausea/vomiting, and sleep disturbances

Online, you will usually see Melanotan I and Melanotan II

Tesamorelin Description: A growth hormone-releasing peptide that targets visceral fat, especially in the abdominal area, while supporting metabolic health

#psychiatry #alcoholism #addiction We use GLP-1 agonists in our practice to help manage clozapine associated weight gain

Unfortunately, the pathway by which SCFAs result in the elevation of IGF-1 is still not well understood